Lungs News and Research

RSS

Merck decides not to advance IMO-2055 development for squamous cell carcinoma of the head and neck

Idera Pharmaceuticals today provides an update on the clinical development of IMO-2055 (EMD 1201081), a TLR9 agonist for cancer treatment being developed by Merck KGaA, Darmstadt, Germany, under its collaboration with Idera.

8 Jul 2011

New NCCN Clinical Practice Guideline on Malignant Pleural Mesothelioma

The National Comprehensive Cancer Network (NCCN), with the support of the NCCN Foundation, announces the latest addition to the library of NCCN Guidelines for Patients, the NCCN Guidelines for Patients: Malignant Pleural Mesothelioma.

8 Jul 2011

Allegro completes $5.4M Series A extension financing

Allegro Diagnostics today announced that it has closed a $5.4M Series A extension financing. The company's existing venture investors, Kodiak Venture Partners and Catalyst Health Ventures, participated in the round.

8 Jul 2011

Enrollment commences in InterMune's Esbriet Phase 3 study for IPF

InterMune today announced that patient enrollment has begun in ASCEND, a new Phase 3 study of pirfenidone for patients who suffer from idiopathic pulmonary fibrosis.

8 Jul 2011

ThromboView gets positive results in study evaluating accuracy and safety

Drug and diagnostic company Agenix Limited (ASX: AGX), today announced the positive results of a study to evaluate the efficacy and accuracy

7 Jul 2011

Half-matched transplants widen donor pool for leukemia and lymphoma

Identifying a suitable donor for leukemia and lymphoma patients who need bone marrow transplants may be far easier now that results of two clinical trials show transplant results with half-matched bone marrow or umbilical cord blood are comparable to fully matched tissue, thanks in large part to the availability of effective antirejection drugs and special post-transplant chemotherapy. The finding means that nearly all patients in need of a transplant can find donors, according to Johns Hopkins scientists who participated in the trials.

7 Jul 2011

Researchers use AFM to characterize ovarian cell structure for cancer diagnosis

Using ovarian surface epithelial cells from mice, researchers from Virginia Tech have released findings from a study that they believe will help in cancer risk assessment, cancer diagnosis, and treatment efficiency in a technical journal: Nanomedicine.

7 Jul 2011

Conference to explore interface between medicine, arts and humanities

The University of Leicester is hosting a conference to be addressed by Jed Mercurio, author of Bodies and creator of the TV series Cardiac Arrest.

7 Jul 2011

Levels of urinary eosinophil protein-X may predict future atopy in asymptomatic children

The signs of atopy may be present long before symptoms begin, even in month-old babies, according to a new research study from Denmark. The study found that the level of urinary eosinophil protein-X (u-EPX), a marker of inflammatory cells, in newborn babies was linked to higher risk of allergic sensitization, nasal eosinophilia and eczema at six years.

7 Jul 2011

Study: Cancer patients with VTE do not benefit from IVCF and fondaparinux

Cancer patients with blood clots -- which occur in one of every 200 cancer patients and are the second most common cause of death among cancer patients -- gain no benefit from the insertion of an inferior vena cava filter (IVCF) to the anticoagulant medication fondaparinux (Arixtra), according to research presented today at the 14th World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer.

7 Jul 2011

Endoscopic testing prior to lung cancer surgery improves quality of life

Patients who underwent endoscopic testing prior to surgery for lung cancer had significantly better quality of life at the end of the staging process, with no significant difference in costs between the two strategies, according to data presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

7 Jul 2011

Amrubicin vs. topotecan Phase III trial against lung cancer presented at IASLC conference

Lung cancer patients given amrubicin (Calsed) as a second-line therapy had a significantly improved response rate and longer progression-free survival than patients treated with topotecan (Hycamtin), according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

7 Jul 2011

TGen presents two key studies at 14th World Conference on Lung Cancer

The Translational Genomics Research Institute (TGen) is presenting two key studies, including one today, at the 14th World Conference on Lung Cancer, July 3-7 in Amsterdam.

7 Jul 2011

Simpler antibiotic combination could help prevent TB in patients with and without HIV

Johns Hopkins and South African scientists have further compelling evidence that new, simpler and shorter treatments with antibiotic drugs could dramatically help prevent tens of millions of people worldwide already infected with the bacterium responsible for tuberculosis, and especially those co-infected with HIV, from developing full-blown TB.

7 Jul 2011

Scientists reveal that 'detox' protein could trigger pancreatic, lung cancer development

CANCER RESEARCH UK scientists have revealed that a 'detox' protein which mops up harmful 'reactive oxygen' in cells could also trigger pancreatic and lung cancer development, according to a study published in Nature, today.

7 Jul 2011

Ovarian cells are stiffer and more viscous when benign

6 Jul 2011

Increase in lung cancer resection rate linked to increased investment in thoracic surgical expertise

Increased investment in specialist thoracic surgical expertise can lead to a significant rise in the lung cancer resection rate, based on data from England between 2008 and 2009 that was presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC).

6 Jul 2011

New CRM simulation model for Canadian Partnership Against Cancer

If Canada's smoking rates were cut by half to an average national rate of 11% within five years, it would result in 35,900 fewer cases of lung cancer by 2030 and save $656 million in treatment costs, according to analysis using a new web-enabled platform developed for the Canadian Partnership Against Cancer and presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

6 Jul 2011

Air traffic pollution impacts growth and development of unborn children

A UK academic is calling for a nationwide study into the effects traffic pollution has on asthma sufferers after his own research in Cairo highlighted health problems in children who may even be affected while still in the womb.

6 Jul 2011

Review of non-smoker patient with lung cancer to be presented at IASLC conference

A first-of-its-kind study of a patient with lung cancer who never smoked will be presented today by TGen and the Virginia G. Piper Cancer Center at Scottsdale Healthcare at the 14th World Conference on Lung Cancer, July 3-7 in Amsterdam.

6 Jul 2011